<DOC>
	<DOCNO>NCT00648154</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan 's letrozole 2.5 mg tablet Novartis ' Femara® 2.5 mg tablet follow single , oral 2.5 mg ( 1 x 2.5 mg ) dose administer fed condition .</brief_summary>
	<brief_title>Food Study Letrozole Tablets 2.5 mg Femara® Tablets 2.5 mg</brief_title>
	<detailed_description />
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Age : 40 year old . 2 . Sex : Females . 3 . Weight : At least 52 kg ( 115 lb ) within 30 % Ideal Body Weight ( IBW ) , reference Table `` '' Desirable Weights Adults '' '' Metropolitan Life Insurance Company , 1999 ( See Part II : ADMINISTRATIVE ASPECTS OF HUMAN BIOAVAILABILITY PROTOCOLS ) . 4 . Absence menses one year postmenopausal subject , least 6 week oophorectomized subject . ( For oophorectomized subject , operative report document bilateral oophorectomy surgical pathology report document absence malignant disease . ) 5 . Baseline FSH 17βestradiol serum level consistent postmenopausal status confirm within 72 hour initiation study medication ( FSH great equal 40 mIU/mL ; 17βestradiol less equal 31 pg/mL ) . 6 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , 12lead ECG , Hepatitis B , Hepatitis C HIV test , urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine , methadone ) perform within 21 day initial dose study medication . 7 . The physical examination shall include pelvic breast exam . 1 . Pelvic finding consistent hypoestrogenemia . 2 . A mammogram require perform within last 12 month . 3 . A Papanicolaou ( `` Pap '' ) smear require subject intact uterus cervix perform within last 6 month . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobaccocontaining product within 1 year start study . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 5 . A positive test drug include urine drug screen . 6 . History drug and/or alcohol abuse . 3 . Medications : 1 . Use prescription overthecounter ( OTC ) medication within 14 day prior initial dose study medication . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 3 . Use hormonal replacement therapy within 3 month prior initial dose study medication . 4 . Diseases : 1 . History significant chronic disease ( limited ) : 1 . Thrombotic disorder . 2 . Coronary artery cerebrovascular disease . 3 . Liver , kidney gallbladder dysfunction/disorder ( ) . 4 . Diabetes endocrinological disease . 5 . Estrogendependent neoplasia . 6 . Postmenopausal uterine bleeding . 7 . Endometrial hyperplasia . 2 . Acute illness time either prestudy medical evaluation dosing . 3 . A positive HIV , Hepatitis B , Hepatitis C test . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity letrozole , inactive ingredient . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 7 day drug administration .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>